Breaking Finance News

BidaskClub upgraded ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to Sell in a report released today.

Yesterday ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) traded -1.91% lower at $29.27. The company’s 50-day moving average is $32.35 and its 200-day moving average is $31.54. The last closing price is down 15.59% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 1,080,804 shares of the stock traded hands, down from an average trading volume of 1,456,330

BidaskClub has upgraded ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to Sell in a report released on 6/21/2017.

See Chart Below

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc. has a 52 week low of $20.68 and a 52 week high of $40.83 The company’s market cap is currently $0.

In addition to BidaskClub reporting its stock price target, a total of 10 brokers have issued a research note on the company. The average stock price target is $45.70 with 2 brokers rating the stock a strong buy, 7 brokers rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *